🇺🇸 FDA

Company profile · Sponsor

Boehringer

Boehringer Ingelheim International GmbH

EC061E8 · EMA pharma Ingelheim am Rhein, DE
Pipeline
24
Drugs
0
Patents
0

Quick answer

Boehringer (EC061E8) is a pharma company. headquartered in Ingelheim am Rhein, DE. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EC061E8
Exchange EMA
Company type pharma
Headquarters Ingelheim am Rhein, DE

Pipeline (24)

Search pipeline →

  1. An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)

    Boehringer

    Schizophrenia

    phase 3 other active

    1 trial

  2. Avtozma 20 mg/mL concentrate for solution for infusion., BI 764532, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Etoposid Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Boehringer

    advanced or metastatic extrapulmonary neuroendocrine carcinoma

    phase 3 small molecule active

    1 trial

  3. BI 1015550, BI 1015550

    Boehringer

    idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF)

    phase 3 small molecule active

    1 trial

  4. BI 1015550, Placebo matching BI 1015550, BI 1015550

    Boehringer

    Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

    phase 3 small molecule active

    1 trial

  5. BI 1015550, Placebo matching nerandomilast (BI 1015550)

    Boehringer

    Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD)

    phase 3 small molecule active

    1 trial

  6. BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, Placebo

    Boehringer

    Obesity

    phase 3 small molecule active

    1 trial

  7. BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, Placebo, BI 456906, BI 456906

    Boehringer

    Obesity

    phase 3 small molecule active

    1 trial

  8. BI 456906, BI 456906, BI 456906, BI 456906, Placebo matching products 1 to 7 (pre-filled syringe, filling volume: 0.5 mL), BI 456906, BI 456906, BI 456906

    Boehringer

    Obesity

    phase 3 small molecule active

    1 trial

  9. BI 456906, Placebo, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906

    Boehringer

    Obesity, Diabetes mellitus type II

    phase 3 small molecule active

    1 trial

  10. BI 764198, Placebo matching BI 764198

    Boehringer

    Focal segmental glomerulosclerosis

    phase 3 small molecule active

    1 trial

  11. BI 907828, BI 907828, BI 907828

    Boehringer

    dedifferentiated liposarcoma

    phase 3 small molecule active

    1 trial

  12. BI 907828, BI 907828, Doxorubicin-Ebewe, 2 mg/ml, koncentrat do sporządzania roztworu do infuzji, BI 907828

    Boehringer

    Advanced dedifferentiated liposarcoma

    phase 3 small molecule active

    1 trial

  13. EMPAGLIFLOZIN, BI 690517, Placebo matching vicadrostat

    Boehringer

    Heart failure

    phase 3 small molecule active

    1 trial

  14. EMPAGLIFLOZIN, Placebo matching BI 690517, BI 690517

    Boehringer

    Heart failure (HF)

    phase 3 small molecule active

    1 trial

  15. Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat, BI 690517

    Boehringer

    Type 2 diabetes, hypertension, cardiovascular disease

    phase 3 small molecule active

    1 trial

  16. Jardiance 10 mg film-coated tablets, empagliflozin, Placebo matching empagliflozin, film-coated tablets

    Boehringer

    Chronic kidney disease in paediatric patients

    phase 3 small molecule active

    1 trial

  17. KEYTRUDA 25 mg/mL concentrate for solution for infusion, BI 1810631, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Boehringer

    non-squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  18. Metalyse 5 000 units (25 mg) powder for solution for injection

    Boehringer

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  19. OPDIVO 10 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, BI 1810631, Tecentriq 1 200 mg concentrate for solution for infusion

    Boehringer

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  20. Placebo matching BI 1015550, BI 1015550, BI 1015550

    Boehringer

    Interstitial lung diseases, Familial pulmonary fibrosis, Pulmonary fibrosis

    phase 3 small molecule active

    1 trial

  21. Placebo matching BI 1291583, BI 1291583

    Boehringer

    Bronchiectasis

    phase 3 small molecule active

    1 trial

  22. Placebo matching to spesolimab

    Boehringer

    Pyoderma gangrenosum

    phase 3 small molecule active

    1 trial

  23. Spesolimab, Placebo matching to Spesolimab

    Boehringer

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  24. Tecentriq 1 200 mg concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Etoposid Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BI 764532, RoActemra 20 mg/mL concentrate for solution for infusion

    Boehringer

    small cell lung cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is Boehringer?

Boehringer (EC061E8) is a pharma company. headquartered in Ingelheim am Rhein, DE. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Boehringer sponsor?

We track 24 ClinicalTrials.gov-linked programs for Boehringer, including An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X) and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Boehringer company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.